Comparative Pharmacology
Head-to-head clinical analysis: SPRX 105 versus TYZAVAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SPRX 105 versus TYZAVAN.
SPRX-105 vs TYZAVAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SPRX-105 is a dual dopamine D2 and serotonin 5-HT1A receptor partial agonist, functioning as a postsynaptic antagonist and presynaptic agonist at D2 receptors, and as a partial agonist at 5-HT1A receptors, modulating neurotransmitter release.
Levodopa is converted to dopamine in the brain, replenishing depleted dopamine levels in the striatum, improving motor function. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing its central availability.
SPRX-105 is administered orally at a dose of 50 mg once daily.
200 mg orally once daily, taken with food.
None Documented
None Documented
12-15 hours in healthy adults; extended to 24-30 hours in renal impairment.
Terminal elimination half-life is 12–15 hours in patients with normal renal function; prolonged to 30–50 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal (70-80% unchanged) with 15-20% biliary/fecal elimination.
Renal excretion (70–80% unchanged); biliary/fecal excretion accounts for 15–20% as metabolites.
Category C
Category C
Unknown
Unknown